By 2030, it is anticipated that the Nigeria infectious disease therapeutics market will reach a value of $163.7 Mn from $107.9 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030. The Infectious Disease Therapeutics in Nigeria is dominated by a few domestic pharmaceutical companies such as Fidson Healthcare, Emzor Pharmaceutical and Afrigen Biologics. The Infectious Disease Therapeutics market in Nigeria is segmented into different therapeutic areas and different diseases type. The major factors affecting the Nigeria infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of Nigeria.
By 2030, it is anticipated that the Nigeria infectious disease therapeutics market will reach a value of $163.7 Mn from $107.9 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030.
Nigeria is a lower middle-income, developing country located in West Africa with a coast on the Gulf of Guinea and the Atlantic Ocean. According to the World Factbook, Nigeria is particularly vulnerable to the infectious diseases listed below. Food or waterborne infections include bacterial and protozoal diarrhoea, hepatitis A, and typhoid fever. Water-borne infectious diseases such as leptospirosis and schistosomiasis are common in Nigeria. Rabies, malaria, dengue fever, yellow fever, meningococcal meningitis, and Lassa fever are Nigeria's other main infectious diseases.
Nigeria is also involved in vaccine development, with the National Primary Health Care Development Agency in charge of vaccine development and delivery. The agency manufactures a variety of vaccines, including those against polio, measles, and yellow fever. Nigeria's government spends 3.4% of its GDP on healthcare.
Market Growth Drivers Analysis
The President's Malaria Initiative (PMI), led by USAID and the CDC, collaborates with other organisations to assist over 41 Mn Nigerians. Despite the challenges created by COVID-19 in 2020, the PMI was able to assist Nigeria in distributing 14.7 Mn malaria treatment tablets, 8.2 Mn of which went to pregnant women and children. These aspects could boost Nigeria's infectious disease therapeutics market.
Market Restraints
The creation of novel pharmaceuticals and treatments necessitates substantial investment, and finance can be a barrier for many research efforts. Due to fiscal restrictions or conflicting objectives, funding for research and development in Nigeria may be constrained. Developing new pharmaceuticals and treatments necessitates adherence to regulatory rules established by agencies such as Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC). Manufacturing activity accounts for only 10% of Nigeria's GDP, despite the Made in Nigeria (MINE) project's goal of increasing it to 20%. These factors may deter new entrants into the Nigeria infectious disease therapeutics market.
Key Players
The National Agency for Food and Drug Administration and Control regulates infectious disease therapies in Nigeria (NAFDAC). The NAFDAC oversees assessing the safety, efficacy, and quality of all medications and medical equipment, including those used to treat infectious diseases. The National Health Insurance Scheme (NHIS) oversees the national health insurance programme, which covers a variety of healthcare services, including pharmaceuticals and infectious disease treatments.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Nigeria infectious disease therapeutics market will reach a value of $163.7 Mn from $107.9 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030.
In Nigeria, the regulation of infectious disease therapeutics is overseen by the National Agency for Food and Drug Administration and Control (NAFDAC).
The Infectious Disease Therapeutics in Nigeria is dominated by a few domestic pharmaceutical companies such as Fidson Healthcare, Emzor Pharmaceutical and Afrigen Biologics.